Key Highlights:
- Mango Sciences Inc. has partnered with ImmunoAdoptive Cell Therapy to help more patients access the CAR-T therapy NexCAR19 for treating leukaemia and lymphoma in India, focusing on improving affordability for patients who need advanced cancer treatment.
- Under the partnership, patients receiving NexCAR19 can opt for flexible financing options, including 0% interest EMI plans of up to INR 10 lakhs. Clinically eligible patients may also benefit from value-based offerings of up to INR 10 lakhs designed to ease the financial burden of CAR-T therapy.
- The program will initially roll out at select healthcare centers, combining Mango Sciences’ data-driven care approach with ImmunoACT’s indigenous CAR-T innovation to make cutting-edge cancer therapies more accessible and practical for patients across India.
Implication:
This financing model slashes NexCAR19’s effective cost by 30-40%, challenging global CAR-T players like Novartis/Kite while accelerating adoption in Tier-2/3 cities where 70% of India’s 60K+ annual blood cancer cases originate.
ImmunoACT could triple patient volumes within 18 months via EMI accessibility, pressuring hospital cash-pay models and drawing PE into value-based oncology financing platforms.
Success establishes India as low-cost CAR-T manufacturing/export hub, competing with China for $5B+ global access market while supporting PLI-driven cell/gene therapy scale-up.
Source: Businesswire
